8-K: Jasper Therapeutics Enters $100 Million Open Market Sale Agreement with Jefferies, Terminates Cantor Fitzgerald Agreement

Jasper Therapeutics has entered into a sales agreement with Jefferies for potential stock sales up to $100 million and terminated its previous agreement with Cantor Fitzgerald.

Summary

• Jasper Therapeutics, Inc. entered into an Open Market Sale AgreementSM with Jefferies LLC on March 19, 2025, allowing the company to offer and sell shares of its voting common stock up to an aggregate offering price of $100,000,000.
• Jefferies will act as a sales agent or principal and receive compensation of 3.0% of the gross sales price per share sold.
• The company is not obligated to sell any shares under the Sales Agreement.
• Concurrently, Jasper Therapeutics terminated its Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co. effective March 14, 2025.
• No shares were sold under the Cantor Sales Agreement from November 10, 2022, to March 14, 2025.
• The new sales agreement was made pursuant to the company's shelf registration statement on Form S-3 (Registration Statement No. 333285914 ), filed with the Securities and Exchange Commission (the SEC) on March 19, 2025.

Sentiment

Score: 5

Explanation: Neutral sentiment as the announcement is a standard financial transaction. The capital raise provides financial flexibility, but also introduces potential dilution.

Positives

• The new sales agreement with Jefferies provides Jasper Therapeutics with a flexible mechanism to raise capital.
• Termination of the Cantor Fitzgerald agreement did not result in any material early termination penalties.

Risks

• The company's stock price could be diluted if a significant number of shares are sold under the Open Market Sale Agreement.
• There is no guarantee that the company will be able to sell all or any of the shares under the Sales Agreement.

Future Outlook

The company may offer and sell shares of its common stock from time to time through Jefferies, but there is no obligation to do so.

Industry Context

Open market sale agreements are a common method for biotech companies to raise capital, providing flexibility in timing and amount raised based on market conditions and company needs.

Comparison to Industry Standards

• Similar agreements are common in the biotech industry, with companies like [Comparable Biotech Company A] and [Comparable Biotech Company B] having utilized similar open market sale agreements to raise capital.
• The 3.0% commission to Jefferies is within the typical range for such agreements, which can vary based on the size and complexity of the offering.

Stakeholder Impact

• Shareholders may experience dilution if the company sells a significant number of shares.
• The capital raise could provide the company with additional resources to fund its operations and research and development activities.

Key Dates

Keywords

Open Market Sale Agreement, Jefferies LLC, Cantor Fitzgerald, Common Stock, Capital Raise, Share Offering, Jasper Therapeutics